查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
病毒载体和质粒 DNA 製造市场 - 增长、未来展望、竞争分析，2023-2031 年
市场调查报告书
商品编码
1293832

病毒载体和质粒 DNA 製造市场 - 增长、未来展望、竞争分析，2023-2031 年

Viral Vectors and Plasmid DNA Manufacturing Market - Growth, Future Prospects and Competitive Analysis, 2023 - 2031
出版日期: | 出版商: Acute Market Reports | 英文 115 Pages | 商品交期: 最快1-2个工作天内

价格

由于对先进基因疗法、疫苗和细胞疗法的需求不断增加，预计 2023 年至 2031 年期间，病毒载体和质粒 DNA 製造市场将以 22.5% 的复合年增长率增长。Masu。 预计未来几年市场收入将以可观的复合年增长率（CAGR）显着增长。 病毒载体和质粒 DNA 是基因治疗和疫苗开发和生产的重要组成部分。 病毒载体，如腺病毒、慢病毒和腺相关病毒（AAV），用于将遗传物质引入靶细胞，并可以改变或修改与各种疾病相关的特定基因。 另一方面，质粒 DNA 作为携带治疗基因的载体，并为细胞内蛋白质合成提供必要的指令。 随着生物技术和基因工程的进步，病毒载体/质粒 DNA 製造市场正在彻底改变医学领域。 基因治疗药物在治疗各种遗传性疾病、罕见疾病和某些类型的癌症方面显示出巨大的潜力。 此外，针对传染病和癌症免疫疗法的疫苗的开发进一步推动了对病毒载体和质粒DNA生产的需求。 COVID-19 大流行导致疫苗和治疗方法的研发活动激增，进一步推动了该市场的增长。 多家製药公司和研究机构致力于利用病毒载体和质粒 DNA 开发 COVID-19 疫苗和疗法。 这场前所未有的全球健康危机凸显了病毒载体和质粒 DNA 製造能力对于应对新出现的传染病和公共卫生挑战的重要性。

基因治疗需求不断增长

病毒载体和质粒 DNA 製造市场是由基因治疗需求不断增长所推动的。 基因治疗是一种通过将功能基因引入患者细胞来治疗多种遗传性疾病的有前途的方法。 肌营养不良症、囊性纤维化和血友病等遗传性疾病的患病率日益增加，推动了对基因治疗的需求。 根据《美国医学会杂誌》（JAMA）发表的一项研究，基因治疗在多种遗传性疾病的临床试验中显示出显着的治疗效果。 针对以前无法治疗的疾病和治疗选择有限的疾病的基因治疗的成功，创造了对其生产中使用的病毒载体和质粒 DNA 的强劲市场需求。

病毒载体技术的进展

病毒载体技术的进步在推动病毒载体和质粒 DNA 製造市场的增长方面发挥着关键作用。 研究人员和生物製药公司不断致力于提高基因治疗和疫苗中使用的病毒载体的效率、安全性和特异性。 例如，具有增强的基因转移能力和降低的免疫原性的新一代腺相关病毒（AAV）的开发促成了多项基因治疗试验的成功。 发表在《分子治疗》杂誌上的一项研究也证明了新型 AAV 变体实现有效基因转移的潜力。 病毒载体技术的进步不仅提高了基因治疗的功效，而且将其应用扩展到各个治疗领域，进一步增加了对病毒载体/质粒DNA生产的需求。

增加生物技术研发投资

生物技术研发投资的增加推动了病毒载体和质粒 DNA 製造市场的发展。 各国政府、製药公司和研究机构正在投入大量资金来开发基因疗法和疫苗等创新疗法。 例如，美国国立卫生研究院（NIH）在基因治疗研究和支持临床试验方面投入了大量资金。 欧盟 (EU) 还通过其 Horizo□□n 2020 计划投入大量资金，以推进生物技术和基因治疗计划。 这种对研发的投资促进了新技术的发现并导致先进疗法的商业化。 不断增加的财政支持以及对生物技术研究和开发的关注预计将在未来几年推动病毒载体和质粒 DNA 製造市场的发展。

监管挑战和安全担忧

病毒载体和质粒 DNA 製造市场面临监管挑战和安全问题，这是市场增长的製约因素。 基因治疗药物和疫苗的开发和商业化需要严格的监管流程和安全评估，以确保产品的功效和安全性。 美国食品药品监督管理局 (FDA) 和欧洲药品管理局 (EMA) 等监管机构对病毒载体和质粒 DNA 的製造、质量控制和临床测试制定了严格的指导方针和要求。 对于製造商来说，遵守这些法规既耗时又昂贵，并可能导致产品批准和市场准入的延迟。 此外，对与基因治疗相关的潜在风险（例如免疫反应、脱靶效应和长期安全性）的担忧也对这些疗法的广泛采用构成了挑战。 临床试验中的不良事件和安全报告可能会影响人们对基因治疗的认识和接受度，并影响对病毒载体和质粒 DNA 製造的需求。 例如，围绕治疗 X 连锁严重联合免疫缺陷病 (X-SCID) 的基因治疗试验的安全性问题导致试验暂停。 这些监管挑战和安全问题需要严格的监管合规和持续的研究，以确保基因疗法和疫苗的安全性和有效性，这将成为DNA製造市场的製约因素。

从载体类型来看，腺病毒载体主导市场

病毒载体和质粒DNA製造市场可以按载体类型细分，包括腺病毒、逆转录病毒、腺相关病毒（AAV）、慢病毒和质粒。 其中，AAV 预计在 2023 年至 2031 年的预测期内復合年增长率最高。 AAV载体由于能够有效地将治疗基因递送到具有低免疫原性和长期基因表达的靶细胞中，因此在基因治疗应用中引起了相当大的关注。 AAV载体在Luxturna和Zolgensma等已批准的基因治疗药物中的使用证明了AAV载体在治疗遗传性疾病方面的潜力。 因此，对 AAV 载体的需求增加，推动了市场复合年增长率的增长。 在病毒载体和质粒DNA製造市场中，腺病毒载体将在2022年占据销售额的最高份额。 腺病毒载体因其高转导效率和容纳大DNA插入片段的能力而广泛应用于基因治疗研究和临床试验。 特别是，它在多种基因治疗应用中取得了成功，例如癌症免疫治疗和疫苗开发。 此外，稳健的腺病毒载体製造工艺和既定方案有助于腺病毒载体在市场上占据主导收入地位。 包括慢病毒在内的逆转录病毒载体也占据了很大的收入份额，这主要是由于它们在 CAR-T 细胞疗法和基因工程细胞疗法中的使用。 质粒作为基因克隆和重组DNA技术的重要工具，为市场带来了收入，但增长率相对较低。 其他载体类型，例如单纯疱疹病毒（HSV）载体和痘苗病毒载体，市场份额较小。 总之，腺病毒载体预计将产生最高的收入，而 AAV 载体由于其有前景的基因治疗应用，预计将创下最高的复合年增长率。

北美地区引领收入，亚太地区引领增长

就收入而言，到 2022 年，北美将占据病毒载体和质粒 DNA 製造市场的很大份额。 该地区拥有成熟的生物製药产业、强大的研究基础设施和有利的监管框架，促进基因疗法和疫苗的开发和商业化。 此外，研发活动的投资不断增加，尤其是在美国，这有助于市场收入的增长。 此外，欧洲是病毒载体/质粒DNA製造市场的重要地区，对盈利的贡献很高。 主要生物製药公司的存在、生物技术研究的进步以及政府的大力支持正在推动该地区的市场增长。 预计 2023 年至 2031 年预测期内，亚太地区的复合年增长率最高。 由于研发投资增加、医疗保健支出增加以及对个性化医疗的日益关注等因素，该地区生物技术领域呈现快速增长。 中国、日本和印度等国家利用其科学专业知识和扩大生物製药能力，已成为病毒载体和质粒 DNA 製造市场的主要参与者。 拉美、中东/非洲等地区正在努力改善医疗基础设施，引进先进医疗技术，市场稳步增长。

预测期内市场竞争将会加剧

病毒载体和质粒DNA製造市场竞争激烈，几家大公司积极参与用于基因治疗和疫苗的病毒载体和质粒DNA的开发和生产。 这些公司专注于战略举措，以提高市场占有率并获得竞争优势。 Lonza Group 是市场领导者之一，它是一家全球合同开发和製造组织 (CDMO)。 Lonza 提供广泛的服务，包括病毒载体製造、质粒 DNA 製造和工艺开发。 市场领导者和其他人采取的关键战略包括投资研发活动以增强製造工艺、扩大产能以满足不断增长的需求以及利用新技术进入和进入市场，其中包括建立战略合作伙伴关係和联盟以扩大规模。 这些公司还专注于确保监管合规、质量保证和遵守良好生产规范，以满足基因治疗和疫苗行业的严格要求。 此外，新兴公司和初创企业凭藉创新技术和平台进入市场，进一步加剧了病毒载体和质粒DNA製造市场的竞争。 这些公司正在利用生物技术和基因工程的进步来开发新型病毒载体和质粒 DNA 製造方法。

内容

第 1 章前言

  • 报告内容
    • 报告的目的
    • 目标受众
    • 主要产品
  • 市场细分
  • 调查方法

第 2 章执行摘要

第 3 章病毒载体和质粒 DNA 製造市场：竞争分析

  • 主要供应商的市场定位
  • 供应商采取的策略
  • 主要产业战略
  • 层级分析：2022 年与 2031 年

第 4 章病毒载体和质粒 DNA 製造市场：宏观分析和市场动态

  • 简介
  • 2021-2031 年全球病毒载体和质粒 DNA 製造市场价值
  • 市场动态
    • 市场促进因素
    • 市场抑制因素
    • 主要问题
    • 主要机会
  • 促进因素和抑制因素的影响分析
  • 跷跷板分析

第 5 章病毒载体和质粒 DNA 製造市场：按载体类型 2021-2031

  • 市场概况
  • 增长和盈利分析：2022 年与 2031 年
  • 市场细分
    • 腺病毒
    • 逆转录病毒
    • 腺相关病毒（AAV）
    • 慢病毒
    • 质粒
    • 其他

第 6 章病毒载体和质粒 DNA 製造市场：按工作流程 2021-2031

  • 市场概况
  • 增长和盈利分析：2022 年与 2031 年
  • 市场细分
    • 上游製造流程
      • 向量放大/扩展
      • 载体恢復/收集
    • 下游製造流程
      • 细化
      • 填充和整理

第 7 章病毒载体和质粒 DNA 製造市场：按应用分类 2021-2031

  • 市场概况
  • 增长和盈利分析：2022 年与 2031 年
  • 市场细分
    • 反义/RNAi疗法
    • 基因治疗
    • 细胞疗法
    • 疫苗开发
    • 研究用途

第 8 章病毒载体和质粒 DNA 製造市场：按最终用途 2021-2031

  • 市场概况
  • 增长和盈利分析：2022 年与 2031 年
  • 市场细分
    • 製药和生物製药公司
    • 研究院

第 9 章 2021-2031 年按疾病划分的病毒载体和质粒 DNA 製造市场

  • 市场概况
  • 增长和盈利分析：2022 年与 2031 年
  • 市场细分
    • 癌症
    • 遗传性疾病
    • 感染
    • 其他

第 10 章 2021-2031 年北美病毒载体和质粒 DNA 製造市场

  • 市场概况
  • 病毒载体和质粒 DNA 製造市场：按载体类型 2021-2031
  • 病毒载体和质粒 DNA 製造市场：按工作流程 2021-2031
  • 病毒载体和质粒 DNA 製造市场：按应用 2021-2031
  • 病毒载体和质粒 DNA 製造市场：按最终用途 2021-2031
  • 病毒载体和质粒 DNA 製造市场：按疾病分类 2021-2031
  • 病毒载体和质粒 DNA 製造市场：按地区 2021-2031
    • 北美
      • 美国
      • 加拿大
      • 北美其他地区

第 11 章英国和欧盟病毒载体和质粒 DNA 製造市场 2021-2031

  • 市场概况
  • 病毒载体和质粒 DNA 製造市场：按载体类型 2021-2031
  • 病毒载体和质粒 DNA 製造市场：按工作流程 2021-2031
  • 病毒载体和质粒 DNA 製造市场：按应用 2021-2031
  • 病毒载体和质粒 DNA 製造市场：按最终用途 2021-2031
  • 病毒载体和质粒 DNA 製造市场：按疾病分类 2021-2031
  • 病毒载体和质粒 DNA 製造市场：按地区 2021-2031
    • 英国/欧盟
      • 英国
      • 德国
      • 西班牙
      • 意大利
      • 法国
      • 其他欧洲地区

第 12 章亚太地区病毒载体和质粒 DNA 製造市场 2021-2031

  • 市场概况
  • 病毒载体和质粒 DNA 製造市场：按载体类型 2021-2031
  • 病毒载体和质粒 DNA 製造市场：按工作流程 2021-2031
  • 病毒载体和质粒 DNA 製造市场：按应用 2021-2031
  • 病毒载体和质粒 DNA 製造市场：按最终用途 2021-2031
  • 病毒载体和质粒 DNA 製造市场：按疾病分类 2021-2031
  • 病毒载体和质粒 DNA 製造市场：按地区 2021-2031
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 亚太地区其他地区

第 13 章 2021-2031 年拉丁美洲病毒载体和质粒 DNA 製造市场

  • 市场概况
  • 病毒载体和质粒 DNA 製造市场：按载体类型 2021-2031
  • 病毒载体和质粒 DNA 製造市场：按工作流程 2021-2031
  • 病毒载体和质粒 DNA 製造市场：按应用 2021-2031
  • 病毒载体和质粒 DNA 製造市场：按最终用途 2021-2031
  • 病毒载体和质粒 DNA 製造市场：按疾病分类 2021-2031
  • 病毒载体和质粒 DNA 製造市场：按地区 2021-2031
    • 拉丁美洲
      • 巴西
      • 墨西哥
      • 其他拉丁美洲地区

第 14 章中东和非洲病毒载体和质粒 DNA 製造市场 2021-2031

  • 市场概况
  • 病毒载体和质粒 DNA 製造市场：按载体类型 2021-2031
  • 病毒载体和质粒 DNA 製造市场：按工作流程 2021-2031
  • 病毒载体和质粒 DNA 製造市场：按应用 2021-2031
  • 病毒载体和质粒 DNA 製造市场：按最终用途 2021-2031
  • 病毒载体和质粒 DNA 製造市场：按疾病分类 2021-2031
  • 病毒载体和质粒 DNA 製造市场：按地区 2021-2031
    • 中东和非洲
      • 海湾合作委员会
      • 非洲
      • 其他中东和非洲地区

第 15 章公司简介

  • Lonza
  • Catapult
  • uniQure N.V.
  • FUJIFILM Diosynth Biotechnologies
  • Kaneka Eurogentec S.A.
  • Oxford Biomedica
  • Spark Therapeutics Inc.
  • Cobrabiologics
  • Merck KGaA
  • 其他特色公司
Product Code: 139601-06-23

The viral vectors and plasmid DNA manufacturing market is expected to grow at a CAGR of 22.5% during the forecast period of 2023 to 2031, driven by the increasing demand for advanced gene therapies, vaccines, and cell-based therapies. The market revenue is expected to witness substantial growth in the coming years, with a promising compound annual growth rate (CAGR).Viral vectors and plasmid DNA are essential components in the development and production of gene therapies and vaccines. Viral vectors, such as adenoviruses, lentiviruses, and adeno-associated viruses (AAVs), are used to deliver genetic material into target cells, enabling the modification or correction of specific genes associated with various diseases. Plasmid DNA, on the other hand, serves as a vehicle for carrying therapeutic genes, providing the necessary instructions for protein synthesis within cells.The market for viral vectors and plasmid DNA manufacturing is driven by advancements in biotechnology and genetic engineering, which have revolutionized the field of medicine. Gene therapies have shown tremendous potential in treating a range of genetic disorders, rare diseases, and certain types of cancer. Additionally, the development of vaccines targeting infectious diseases and immunotherapies for cancer has further propelled the demand for viral vectors and plasmid DNA manufacturing.The COVID-19 pandemic has further accelerated the growth of this market, with a surge in research and development activities to develop vaccines and treatments. Several pharmaceutical companies and research organizations have focused their efforts on leveraging viral vectors and plasmid DNA to develop COVID-19 vaccines and therapeutics. This unprecedented global health crisis has highlighted the importance of viral vectors and plasmid DNA manufacturing capabilities in addressing emerging infectious diseases and public health challenges.

Growing Demand for Gene Therapies

The viral vectors and plasmid DNA manufacturing market is driven by the growing demand for gene therapies. Gene therapy offers a promising approach to treat a wide range of genetic disorders and inherited diseases by introducing functional genes into patients' cells. The increasing prevalence of genetic diseases, such as muscular dystrophy, cystic fibrosis, and hemophilia, has fuelled the demand for gene therapies. According to a study published in the Journal of the American Medical Association (JAMA), gene therapy has shown significant therapeutic benefits in clinical trials for various genetic disorders. The success of gene therapies in treating diseases that were previously untreatable or had limited treatment options has generated a strong market demand for viral vectors and plasmid DNA used in their manufacturing.

Advancements in Viral Vector Technology

Advancements in viral vector technology play a crucial role in driving the growth of the viral vectors and plasmid DNA manufacturing market. Researchers and biopharmaceutical companies are constantly working on improving the efficiency, safety, and specificity of viral vectors used in gene therapies and vaccines. For example, the development of new generation adeno-associated viruses (AAVs) with enhanced transduction capabilities and reduced immunogenicity has contributed to the success of several gene therapy trials. A study published in the journal Molecular Therapy demonstrated the potential of novel AAV variants in achieving efficient gene delivery. These advancements in viral vector technology have not only improved the efficacy of gene therapies but also expanded their application in various therapeutic areas, further driving the demand for viral vectors and plasmid DNA manufacturing.

Increasing Investments in Biotechnology Research and Development

The viral vectors and plasmid DNA manufacturing market is propelled by increasing investments in biotechnology research and development. Governments, pharmaceutical companies, and research institutions are allocating significant funds for the development of innovative therapies, including gene therapies and vaccines. For instance, the National Institutes of Health (NIH) in the United States has invested substantial resources in supporting gene therapy research and clinical trials. The European Union has also committed significant funding through its Horizon 2020 program for advancing biotechnology and gene therapy initiatives. These investments in research and development activities fuel the discovery of novel viral vectors and plasmid DNA manufacturing technologies, leading to the commercialization of advanced therapies. The growing financial support and focus on biotechnology research and development are expected to drive the viral vectors and plasmid DNA manufacturing market in the coming years.

Regulatory Challenges and Safety Concerns

The viral vectors and plasmid DNA manufacturing market faces regulatory challenges and safety concerns that serve as a restraint to its growth. The development and commercialization of gene therapies and vaccines involve stringent regulatory processes and safety assessments to ensure the efficacy and safety of these products. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), impose strict guidelines and requirements for the manufacturing, quality control, and clinical testing of viral vectors and plasmid DNA. Compliance with these regulations can be time-consuming and expensive for manufacturers, leading to delays in product approvals and market entry. Additionally, concerns about the potential risks associated with gene therapies, such as immune responses, off-target effects, and long-term safety profiles, pose challenges to the widespread adoption of these therapies. Reports of adverse events and safety issues in clinical trials can impact the perception and acceptance of gene therapies, affecting the demand for viral vectors and plasmid DNA manufacturing. For example, the safety concerns surrounding a gene therapy trial for the treatment of X-linked severe combined immunodeficiency (X-SCID) led to a temporary halt in the trial. These regulatory challenges and safety concerns pose a restraint to the viral vectors and plasmid DNA manufacturing market, necessitating rigorous compliance with regulations and continued research to ensure the safety and efficacy of gene therapies and vaccines.

Adenovirus Vectors Dominates the Market by Vector Type

The viral vectors and plasmid DNA manufacturing market can be segmented based on vector types, including adenovirus, retrovirus, adeno-associated virus (AAV), lentivirus, plasmids, and others. Among these, AAV is expected to witness the highest CAGR during the forecast period of 2023 to 2031. AAV vectors have gained significant attention in gene therapy applications due to their ability to efficiently deliver therapeutic genes to target cells with low immunogenicity and long-term gene expression. The use of AAV vectors in approved gene therapies, such as Luxturna and Zolgensma, has showcased their potential in treating inherited genetic disorders. As a result, the demand for AAV vectors is increasing, driving the growth of the market in terms of CAGR. In terms of revenue, adenovirus vectors held the highest share in 2022 in the viral vectors and plasmid DNA manufacturing market. Adenovirus vectors are widely used in gene therapy research and clinical trials due to their high transduction efficiency and ability to accommodate large DNA inserts. They have demonstrated success in several gene therapy applications, particularly in cancer immunotherapies and vaccine development. Moreover, the robust manufacturing processes and well-established protocols for adenovirus vectors contribute to their dominant revenue position in the market. Retrovirus vectors, including lentivirus, also hold a significant revenue share, primarily driven by their use in CAR-T cell therapies and gene-modified cell therapies. Plasmids, which serve as essential tools in gene cloning and recombinant DNA technology, contribute to the market's revenue but have a comparatively lower growth rate. Other vector types, such as herpes simplex virus (HSV) vectors and vaccinia virus vectors, hold a smaller revenue share in the market. In summary, while adenovirus vectors generate the highest revenue, AAV vectors are expected to witness the highest CAGR, driven by their promising applications in gene therapies.

North America Leads the Revenues While APAC Leads the Growth

North America held a significant share in terms of revenue in the viral vectors and plasmid DNA manufacturing market in 2022. The region has a well-established biopharmaceutical industry, robust research infrastructure, and favorable regulatory frameworks that facilitate the development and commercialization of gene therapies and vaccines. Moreover, increasing investments in research and development activities, particularly in the United States, contribute to the market's revenue growth. Europe is also a prominent region in the viral vectors and plasmid DNA manufacturing market, with a significant revenue contribution. The presence of leading biopharmaceutical companies, advancements in biotechnology research, and strong government support drive the market's growth in this region. In terms of the highest CAGR during the forecast period of 2023 to 2031, Asia Pacific is expected to top the ranl. The region has witnessed rapid growth in the biotechnology sector, driven by factors such as increasing investments in research and development, rising healthcare expenditure, and a growing focus on personalized medicine. Countries like China, Japan, and India are emerging as key players in the viral vectors and plasmid DNA manufacturing market, leveraging their scientific expertise and expanding biopharmaceutical capabilities. Latin America and the Middle East and Africa regions are also witnessing steady growth in the market, driven by the increasing focus on improving healthcare infrastructure and the adoption of advanced medical technologies.

Market Competition to Intensify During the Forecast Period

The viral vectors and plasmid DNA manufacturing market is highly competitive, with several key players actively participating in the development and production of viral vectors and plasmid DNA for gene therapies and vaccines. These companies are focusing on strategic initiatives to strengthen their market presence and gain a competitive edge.One of the top players in the market is Lonza Group, a global contract development and manufacturing organization (CDMO). Lonza offers a wide range of services, including viral vector manufacturing, plasmid DNA production, and process development.Key strategies adopted by top players and others in the market include investing in research and development activities to enhance manufacturing processes, expanding production capacity to meet the growing demand, and establishing strategic partnerships and collaborations to access novel technologies and broaden their market reach. These companies are also focusing on ensuring regulatory compliance, quality assurance, and adherence to good manufacturing practices to meet the stringent requirements of the gene therapy and vaccine industry. Moreover, competition in the viral vectors and plasmid DNA manufacturing market is further intensified by emerging players and start-ups that are entering the market with innovative technologies and platforms. These players are leveraging advancements in biotechnology and genetic engineering to develop novel viral vectors and plasmid DNA manufacturing approaches.

Historical & Forecast Period

This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2023 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation ofViral Vectors and Plasmid DNA Manufacturing market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Viral Vectors and Plasmid DNA Manufacturing market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Vector Type

  • Adenovirus
  • Retrovirus
  • Adeno-Associated Virus (AAV)
  • Lentivirus
  • Plasmids
  • Others

Workflow

  • Upstream Manufacturing
  • Vector Amplification & Expansion
  • Vector Recovery/Harvesting
  • Downstream Manufacturing
  • Purification
  • Fill Finish

Application

  • Antisense & RNAi Therapy
  • Gene Therapy
  • Cell Therapy
  • Vaccinology
  • Research Applications

End-use

  • Pharmaceutical and Biopharmaceutical Companies
  • Research Institutes

Disease

  • Cancer
  • Genetic Disorders
  • Infectious Diseases
  • Others

Region Segment (2021-2031; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Viral Vectors and Plasmid DNA Manufacturing market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2031.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Viral Vectors and Plasmid DNA Manufacturing market?
  • Which is the largest regional market for Viral Vectors and Plasmid DNA Manufacturing market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Viral Vectors and Plasmid DNA Manufacturing market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Viral Vectors and Plasmid DNA Manufacturing market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Viral Vectors and Plasmid DNA Manufacturing Market
  • 2.2. Global Viral Vectors and Plasmid DNA Manufacturing Market, By Vector Type, 2022 (US$ Million)
  • 2.3. Global Viral Vectors and Plasmid DNA Manufacturing Market, By Workflow, 2022 (US$ Million)
  • 2.4. Global Viral Vectors and Plasmid DNA Manufacturing Market, By Application, 2022 (US$ Million)
  • 2.5. Global Viral Vectors and Plasmid DNA Manufacturing Market, By End-use, 2022 (US$ Million)
  • 2.6. Global Viral Vectors and Plasmid DNA Manufacturing Market, By Disease, 2022 (US$ Million)
  • 2.7. Global Viral Vectors and Plasmid DNA Manufacturing Market, By Geography, 2022 (US$ Million)
  • 2.8. Attractive Investment Proposition by Geography, 2022

3. Viral Vectors and Plasmid DNA Manufacturing Market: Competitive Analysis

  • 3.1. Market Positioning of Key Viral Vectors and Plasmid DNA Manufacturing Market Vendors
  • 3.2. Strategies Adopted by Viral Vectors and Plasmid DNA Manufacturing Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2022 Versus 2031

4. Viral Vectors and Plasmid DNA Manufacturing Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Viral Vectors and Plasmid DNA Manufacturing Market Value, 2021 - 2031, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 5.3. Market Segmentation
    • 5.3.1. Adenovirus
    • 5.3.2. Retrovirus
    • 5.3.3. Adeno-Associated Virus (AAV)
    • 5.3.4. Lentivirus
    • 5.3.5. Plasmids
    • 5.3.6. Others

6. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 6.3. Market Segmentation
    • 6.3.1. Upstream Manufacturing
      • 6.3.1.1. Vector Amplification & Expansion
      • 6.3.1.2. Vector Recovery/Harvesting
    • 6.3.2. Downstream Manufacturing
      • 6.3.2.1. Purification
      • 6.3.2.2. Fill Finish

7. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)

  • 7.1. Market Overview
  • 7.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 7.3. Market Segmentation
    • 7.3.1. Antisense & RNAi Therapy
    • 7.3.2. Gene Therapy
    • 7.3.3. Cell Therapy
    • 7.3.4. Vaccinology
    • 7.3.5. Research Applications

8. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)

  • 8.1. Market Overview
  • 8.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 8.3. Market Segmentation
    • 8.3.1. Pharmaceutical and Biopharmaceutical Companies
    • 8.3.2. Research Institutes

9. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)

  • 9.1. Market Overview
  • 9.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 9.3. Market Segmentation
    • 9.3.1. Cancer
    • 9.3.2. Genetic Disorders
    • 9.3.3. Infectious Diseases
    • 9.3.4. Others

10. North America Viral Vectors and Plasmid DNA Manufacturing Market, 2021-2031, USD (Million)

  • 10.1. Market Overview
  • 10.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
  • 10.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
  • 10.4. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
  • 10.5. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
  • 10.6. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
  • 10.7.Viral Vectors and Plasmid DNA Manufacturing Market: By Region, 2021-2031, USD (Million)
    • 10.7.1.North America
      • 10.7.1.1. U.S.
        • 10.7.1.1.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 10.7.1.1.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 10.7.1.1.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 10.7.1.1.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 10.7.1.1.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 10.7.1.2. Canada
        • 10.7.1.2.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 10.7.1.2.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 10.7.1.2.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 10.7.1.2.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 10.7.1.2.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 10.7.1.3. Rest of North America
        • 10.7.1.3.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 10.7.1.3.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 10.7.1.3.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 10.7.1.3.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 10.7.1.3.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)

11. UK and European Union Viral Vectors and Plasmid DNA Manufacturing Market, 2021-2031, USD (Million)

  • 11.1. Market Overview
  • 11.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
  • 11.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
  • 11.4. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
  • 11.5. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
  • 11.6. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
  • 11.7.Viral Vectors and Plasmid DNA Manufacturing Market: By Region, 2021-2031, USD (Million)
    • 11.7.1.UK and European Union
      • 11.7.1.1. UK
        • 11.7.1.1.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 11.7.1.1.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 11.7.1.1.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 11.7.1.1.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 11.7.1.1.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 11.7.1.2. Germany
        • 11.7.1.2.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 11.7.1.2.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 11.7.1.2.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 11.7.1.2.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 11.7.1.2.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 11.7.1.3. Spain
        • 11.7.1.3.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 11.7.1.3.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 11.7.1.3.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 11.7.1.3.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 11.7.1.3.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 11.7.1.4. Italy
        • 11.7.1.4.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 11.7.1.4.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 11.7.1.4.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 11.7.1.4.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 11.7.1.4.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 11.7.1.5. France
        • 11.7.1.5.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 11.7.1.5.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 11.7.1.5.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 11.7.1.5.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 11.7.1.5.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 11.7.1.6. Rest of Europe
        • 11.7.1.6.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 11.7.1.6.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 11.7.1.6.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 11.7.1.6.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 11.7.1.6.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)

12. Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market, 2021-2031, USD (Million)

  • 12.1. Market Overview
  • 12.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
  • 12.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
  • 12.4. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
  • 12.5. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
  • 12.6. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
  • 12.7.Viral Vectors and Plasmid DNA Manufacturing Market: By Region, 2021-2031, USD (Million)
    • 12.7.1.Asia Pacific
      • 12.7.1.1. China
        • 12.7.1.1.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 12.7.1.1.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 12.7.1.1.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 12.7.1.1.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 12.7.1.1.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 12.7.1.2. Japan
        • 12.7.1.2.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 12.7.1.2.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 12.7.1.2.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 12.7.1.2.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 12.7.1.2.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 12.7.1.3. India
        • 12.7.1.3.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 12.7.1.3.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 12.7.1.3.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 12.7.1.3.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 12.7.1.3.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 12.7.1.4. Australia
        • 12.7.1.4.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 12.7.1.4.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 12.7.1.4.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 12.7.1.4.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 12.7.1.4.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 12.7.1.5. South Korea
        • 12.7.1.5.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 12.7.1.5.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 12.7.1.5.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 12.7.1.5.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 12.7.1.5.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 12.7.1.6. Rest of Asia Pacific
        • 12.7.1.6.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 12.7.1.6.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 12.7.1.6.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 12.7.1.6.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 12.7.1.6.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)

13. Latin America Viral Vectors and Plasmid DNA Manufacturing Market, 2021-2031, USD (Million)

  • 13.1. Market Overview
  • 13.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
  • 13.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
  • 13.4. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
  • 13.5. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
  • 13.6. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
  • 13.7.Viral Vectors and Plasmid DNA Manufacturing Market: By Region, 2021-2031, USD (Million)
    • 13.7.1.Latin America
      • 13.7.1.1. Brazil
        • 13.7.1.1.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 13.7.1.1.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 13.7.1.1.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 13.7.1.1.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 13.7.1.1.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 13.7.1.2. Mexico
        • 13.7.1.2.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 13.7.1.2.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 13.7.1.2.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 13.7.1.2.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 13.7.1.2.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 13.7.1.3. Rest of Latin America
        • 13.7.1.3.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 13.7.1.3.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 13.7.1.3.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 13.7.1.3.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 13.7.1.3.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)

14. Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market, 2021-2031, USD (Million)

  • 14.1. Market Overview
  • 14.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
  • 14.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
  • 14.4. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
  • 14.5. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
  • 14.6. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
  • 14.7.Viral Vectors and Plasmid DNA Manufacturing Market: By Region, 2021-2031, USD (Million)
    • 14.7.1.Middle East and Africa
      • 14.7.1.1. GCC
        • 14.7.1.1.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 14.7.1.1.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 14.7.1.1.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 14.7.1.1.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 14.7.1.1.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 14.7.1.2. Africa
        • 14.7.1.2.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 14.7.1.2.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 14.7.1.2.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 14.7.1.2.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 14.7.1.2.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 14.7.1.3. Rest of Middle East and Africa
        • 14.7.1.3.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 14.7.1.3.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 14.7.1.3.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 14.7.1.3.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 14.7.1.3.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)

15. Company Profile

  • 15.1. Lonza
    • 15.1.1. Company Overview
    • 15.1.2. Financial Performance
    • 15.1.3. Product Portfolio
    • 15.1.4. Strategic Initiatives
  • 15.2. Catapult
    • 15.2.1. Company Overview
    • 15.2.2. Financial Performance
    • 15.2.3. Product Portfolio
    • 15.2.4. Strategic Initiatives
  • 15.3. uniQure N.V.
    • 15.3.1. Company Overview
    • 15.3.2. Financial Performance
    • 15.3.3. Product Portfolio
    • 15.3.4. Strategic Initiatives
  • 15.4. FUJIFILM Diosynth Biotechnologies
    • 15.4.1. Company Overview
    • 15.4.2. Financial Performance
    • 15.4.3. Product Portfolio
    • 15.4.4. Strategic Initiatives
  • 15.5. Kaneka Eurogentec S.A.
    • 15.5.1. Company Overview
    • 15.5.2. Financial Performance
    • 15.5.3. Product Portfolio
    • 15.5.4. Strategic Initiatives
  • 15.6. Oxford Biomedica
    • 15.6.1. Company Overview
    • 15.6.2. Financial Performance
    • 15.6.3. Product Portfolio
    • 15.6.4. Strategic Initiatives
  • 15.7. Spark Therapeutics, Inc.
    • 15.7.1. Company Overview
    • 15.7.2. Financial Performance
    • 15.7.3. Product Portfolio
    • 15.7.4. Strategic Initiatives
  • 15.8. Cobrabiologics
    • 15.8.1. Company Overview
    • 15.8.2. Financial Performance
    • 15.8.3. Product Portfolio
    • 15.8.4. Strategic Initiatives
  • 15.9. Merck KGaA
    • 15.9.1. Company Overview
    • 15.9.2. Financial Performance
    • 15.9.3. Product Portfolio
    • 15.9.4. Strategic Initiatives
  • 15.10. Other Notable Players
    • 15.10.1. Company Overview
    • 15.10.2. Financial Performance
    • 15.10.3. Product Portfolio
    • 15.10.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 2 Global Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 3 Global Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 4 Global Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 5 Global Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 6 Global Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 7 Global Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 8 North America Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 9 North America Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 10 North America Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 11 North America Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 12 North America Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 13 North America Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 14 North America Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 15 U.S. Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 16 U.S. Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 17 U.S. Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 18 U.S. Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 19 U.S. Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 20 U.S. Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 21 U.S. Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 22 Canada Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 23 Canada Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 24 Canada Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 25 Canada Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 26 Canada Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 27 Canada Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 28 Canada Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 29 Rest of North America Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 30 Rest of North America Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 31 Rest of North America Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 32 Rest of North America Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 33 Rest of North America Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 34 Rest of North America Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 35 Rest of North America Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 36 UK and European Union Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 37 UK and European Union Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 38 UK and European Union Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 39 UK and European Union Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 40 UK and European Union Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 41 UK and European Union Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 42 UK and European Union Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 43 UK Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 44 UK Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 45 UK Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 46 UK Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 47 UK Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 48 UK Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 49 UK Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 50 Germany Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 51 Germany Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 52 Germany Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 53 Germany Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 54 Germany Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 55 Germany Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 56 Germany Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 57 Spain Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 58 Spain Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 59 Spain Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 60 Spain Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 61 Spain Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 62 Spain Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 63 Spain Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 64 Italy Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 65 Italy Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 66 Italy Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 67 Italy Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 68 Italy Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 69 Italy Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 70 Italy Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 71 France Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 72 France Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 73 France Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 74 France Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 75 France Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 76 France Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 77 France Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 78 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 79 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 80 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 81 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 82 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 83 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 84 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 85 Asia Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 86 Asia Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 87 Asia Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 88 Asia Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 89 Asia Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 90 Asia Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 91 Asia Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 92 China Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 93 China Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 94 China Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 95 China Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 96 China Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 97 China Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 98 China Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 99 Japan Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 100 Japan Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 101 Japan Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 102 Japan Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 103 Japan Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 104 Japan Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 105 Japan Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 106 India Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 107 India Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 108 India Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 109 India Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 110 India Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 111 India Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 112 India Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 113 Australia Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 114 Australia Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 115 Australia Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 116 Australia Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 117 Australia Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 118 Australia Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 119 Australia Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 120 South Korea Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 121 South Korea Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 122 South Korea Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 123 South Korea Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 124 South Korea Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 125 South Korea Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 126 South Korea Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 127 Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 128 Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 129 Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 130 Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 131 Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 132 Latin America Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 133 Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 134 Brazil Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 135 Brazil Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 136 Brazil Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 137 Brazil Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 138 Brazil Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 139 Brazil Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 140 Brazil Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 141 Mexico Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 142 Mexico Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 143 Mexico Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 144 Mexico Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 145 Mexico Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 146 Mexico Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 147 Mexico Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 148 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 149 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 150 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 151 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 152 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 153 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 154 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 155 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 156 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 157 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 158 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 159 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 160 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 161 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 162 GCC Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 163 GCC Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 164 GCC Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 165 GCC Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 166 GCC Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 167 GCC Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 168 GCC Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 169 Africa Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 170 Africa Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 171 Africa Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 172 Africa Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 173 Africa Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 174 Africa Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 175 Africa Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 176 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 177 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 178 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 179 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 180 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 181 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 182 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)

List of Figures

  • FIG. 1 Global Viral Vectors and Plasmid DNA Manufacturing Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Viral Vectors and Plasmid DNA Manufacturing Market: Quality Assurance
  • FIG. 5 Global Viral Vectors and Plasmid DNA Manufacturing Market, By Vector Type, 2022
  • FIG. 6 Global Viral Vectors and Plasmid DNA Manufacturing Market, By Workflow, 2022
  • FIG. 7 Global Viral Vectors and Plasmid DNA Manufacturing Market, By Application, 2022
  • FIG. 8 Global Viral Vectors and Plasmid DNA Manufacturing Market, By End-use, 2022
  • FIG. 9 Global Viral Vectors and Plasmid DNA Manufacturing Market, By Disease, 2022
  • FIG. 10 Global Viral Vectors and Plasmid DNA Manufacturing Market, By Geography, 2022
  • FIG. 11 Market Geographical Opportunity Matrix - Global Viral Vectors and Plasmid DNA Manufacturing Market, 2022

FIG. 12Market Positioning of Key Viral Vectors and Plasmid DNA Manufacturing Market Players, 2022

FIG. 13Global Viral Vectors and Plasmid DNA Manufacturing Market - Tier Analysis - Percentage of Revenues by Tier Level, 2022 Versus 2031

  • FIG. 14 Global Viral Vectors and Plasmid DNA Manufacturing Market, By Vector Type, 2022 Vs 2031, %
  • FIG. 15 Global Viral Vectors and Plasmid DNA Manufacturing Market, By Workflow, 2022 Vs 2031, %
  • FIG. 16 Global Viral Vectors and Plasmid DNA Manufacturing Market, By Application, 2022 Vs 2031, %
  • FIG. 17 Global Viral Vectors and Plasmid DNA Manufacturing Market, By End-use, 2022 Vs 2031, %
  • FIG. 18 Global Viral Vectors and Plasmid DNA Manufacturing Market, By Disease, 2022 Vs 2031, %
  • FIG. 19 U.S. Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 20 Canada Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 21 Rest of North America Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 22 UK Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 23 Germany Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 24 Spain Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 25 Italy Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 26 France Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 27 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 28 China Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 29 Japan Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 30 India Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 31 Australia Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 32 South Korea Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 33 Rest of Asia Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 34 Brazil Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 35 Mexico Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 36 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 37 GCC Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 38 Africa Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 39 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031